Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 22, 2022 - Issue 11
Submit an article Journal homepage
1,594
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan

Kentaro Haradaa Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan;b Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanView further author information
,
Shun Yamamotoa Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, JapanView further author information
&
Ken Katoa Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1733-5072View further author information
ORCID Icon
Pages 1333-1338 | Received 25 Jun 2022, Accepted 17 Oct 2022, Published online: 20 Oct 2022

References

  • Elizabeth CS, Jesper L, Rebecca CF, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048–17092.
  • Thrift AP. Barrett’s esophagus and esophageal adenocarcinoma: how common are they really? Dig Dis Sci. 2018;63(8):1988–1996.
  • Vital statistics in Japan, tabulated by Cancer Information Service, National Cancer Center, Japan. cited 2022 May 29]. Available from 2022 May 29: https://ganjoho.jp/reg_stat/statistics/data/dl/en.html
  • National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan. cited 2022 May 29]. Available from 2022 May 29: https://ganjoho.jp/reg_stat/statistics/data/dl/en.html
  • Murphy G, McCormack C, Abedi-Ardekani B, et al. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann Oncol. 2017;28(9):2086–2093.
  • Rustgi AK, El-Serag HB, Ingelfinger JR. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–2509.
  • Yasushi T, Oki E, Ohgaki K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15(2):135–144.
  • Njei N, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–1146.
  • Adenis A, Bennouna J, Etienne PL, et al. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: a randomised phase II trial (E-DIS). Eur J Cancer. 2019;111:12–20.
  • Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22(3):172–176.
  • Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419–423.
  • Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–1272.
  • Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–959.
  • Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.
  • Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111(9):3123–3141.
  • Vogelsang M, Wang Y, Veber N, et al. The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PloS One. 2012;7(5):e36962.
  • Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18(5):631–639.
  • Kato K, Cho BC, Takahashi M, et al., Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to one prior chemotherapy (ATTRACTION-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517.
  • Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–4293.
  • MERCK. Highlights of prescribing information. KEYTRUDA (pembrolizumab) for injection, for intravenous use; 2022.
  • Lala M, Akala O, Chartash E, et al. CT042-pembrolizumab 400 mg Q6W dosing: first clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients. Cancer Res. 2020;80(16_Supplement):CT042.
  • Sun J, Shen L, Shah MA, et al., Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771.
  • Kojima T, Hara H, Tsuji A, et al. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic for esophageal cancer from KEYNOTE-590. Esophagus. 2022;19(4):683–692. Online ahead of print.
  • Doki Y, Ajani JA, Kato K, et al., Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.